{
  "source": "PA-Notification-Daybue.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1411-3\nProgram Prior Authorization/Notification\nMedication Daybue™ (trofinetide)\nP&T Approval Date 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nDaybue is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor-1 (IGF-\n1) indicated for the treatment of Rett syndrome (RTT) in adults and pediatric patients aged 2 years\nand older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Daybue will be approved based on BOTH of the following criteria:\na. Diagnosis of Rett Syndrome (RTT)\n-AND-\nb. Patient is 2 years of age or older\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Daybue will be approved based on the following criterion:\na. Documentation of positive clinical response to Daybue therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n© 2025 UnitedHealthcare Services Inc.\n1\n4. Reference:\n1. Daybue [package insert]. San Diego, CA: Acadia Pharmaceuticals, Inc.; March 2023.\nProgram Prior Authorization/Notification - Daybue™ (trofinetide)\nChange Control\nDate Change\n5/2023 New program.\n5/2024 Annual review. Updated initial approval duration to 12 months.\n5/2025 Annual review. No changes to clinical criteria.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}